Donnelly S C, Strieter R M, Reid P T, Kunkel S L, Burdick M D, Armstrong I, Mackenzie A, Haslett C
University of Edinburgh, Royal Infirmary, United Kingdom.
Ann Intern Med. 1996 Aug 1;125(3):191-6. doi: 10.7326/0003-4819-125-3-199608010-00005.
To determine the relation between 1) intra-alveolar concentrations of the proinflammatory cytokines (tumor necrosis factor, interleukin-1 beta, and interleukin-8) and the anti-inflammatory cytokines (interleukin-10 and interleukin-1 receptor antagonist) in patients with early adult respiratory distress syndrome (ARDS) and 2) subsequent patient mortality rates.
Prospective cohort study.
University medical center.
28 consecutive patients in whom ARDS was prospectively identified during hospitalization and 9 ventilated controls.
Concentrations of proinflammatory cytokines and anti-inflammatory cytokines in bronchoalveolar lavage fluid.
The concentrations of proinflammatory and anti-inflammatory cytokines within the alveolar air spaces were significantly elevated in patients with ARDS compared with controls (P = 0.01 for tumor necrosis factor [median, 90 pg/mL (range, 0 to 2500 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 118 pg/mL) for controls]; P = 0.001 for interleukin-1 beta [median, 179 pg/mL (range, 0 to 2200 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 80 pg/mL) for controls]; P = 0.0001 for interleukin-8 [median, 628 pg/mL (range, 0 to 4700 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 278 pg/mL) for controls]; P = 0.0005 for interleukin-10 [median, 100 pg/mL (range, 0 to 1600 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 50 pg/mL) for controls], and P = 0.002 for interleukin-1 receptor antagonist [median, 820 pg/mL (range, 0 to 18,900 pg/mL) for patients with ARDS; median, 50 pg/mL (range, 0 to 240 pg/mL) for controls]). A highly significant correlation was found between low concentrations of anti-inflammatory cytokines and subsequent patient mortality rates (P = 0.003 for interleukin-10 [median, 120 pg/mL (range, 30 to 1600 pg/mL) for survivors; median, 40 pg/mL (range, 0 to 110 pg/mL) for nonsurvivors]; P = 0.008 for interleukin-1 receptor antagonist [median, 1600 pg/mL (range, 80 to 18,900 pg/mL) for survivors; median, 90 pg/mL (range, 0 to 3400 pg/mL) for nonsurvivors. No significant correlation was found between the concentrations of the proinflammatory cytokines and mortality rates.
Low concentrations of the anti-inflammatory cytokines interleukin-10 and interleukin-1 receptor antagonist in bronchoalveolar lavage fluid obtained from patients with early ARDS are closely associated with poor prognosis. These findings support the hypothesis that failure to mount a localized intrapulmonary anti-inflammatory response early in the pathogenesis of ARDS contributes to more severe organ injury and worse prognosis. Our findings suggest that augmenting anti-inflammatory cytokine defenses would be a beneficial therapeutic approach to patients with ARDS and other inflammatory diseases.
确定1)早期成人呼吸窘迫综合征(ARDS)患者肺泡内促炎细胞因子(肿瘤坏死因子、白细胞介素-1β和白细胞介素-8)和抗炎细胞因子(白细胞介素-10和白细胞介素-1受体拮抗剂)浓度之间的关系,以及2)随后的患者死亡率。
前瞻性队列研究。
大学医学中心。
28例在住院期间前瞻性确诊为ARDS的连续患者和9例通气对照患者。
支气管肺泡灌洗液中促炎细胞因子和抗炎细胞因子的浓度。
与对照组相比,ARDS患者肺泡气腔内促炎和抗炎细胞因子的浓度显著升高(肿瘤坏死因子:ARDS患者中位数为90 pg/mL(范围为0至2500 pg/mL);对照组中位数为0 pg/mL(范围为0至118 pg/mL),P = 0.01;白细胞介素-1β:ARDS患者中位数为179 pg/mL(范围为0至2200 pg/mL);对照组中位数为0 pg/mL(范围为0至80 pg/mL),P = 0.001;白细胞介素-8:ARDS患者中位数为628 pg/mL(范围为0至4700 pg/mL);对照组中位数为0 pg/mL(范围为0至278 pg/mL),P = 0.0001;白细胞介素-10:ARDS患者中位数为100 pg/mL(范围为0至1600 pg/mL);对照组中位数为0 pg/mL(范围为0至50 pg/mL),P = 0.0005;白细胞介素-1受体拮抗剂:ARDS患者中位数为820 pg/mL(范围为0至18,900 pg/mL);对照组中位数为50 pg/mL(范围为0至240 pg/mL),P = 0.002)。抗炎细胞因子低浓度与随后的患者死亡率之间存在高度显著相关性(白细胞介素-10:幸存者中位数为120 pg/mL(范围为30至1600 pg/mL);非幸存者中位数为40 pg/mL(范围为0至110 pg/mL),P = 0.003;白细胞介素-1受体拮抗剂:幸存者中位数为1600 pg/mL(范围为80至18,900 pg/mL);非幸存者中位数为90 pg/mL(范围为0至3400 pg/mL),P = 0.008)。促炎细胞因子浓度与死亡率之间未发现显著相关性。
早期ARDS患者支气管肺泡灌洗液中抗炎细胞因子白细胞介素-10和白细胞介素-1受体拮抗剂浓度低与预后不良密切相关。这些发现支持以下假设:在ARDS发病机制早期未能启动局部肺内抗炎反应会导致更严重的器官损伤和更差的预后。我们的发现表明,增强抗炎细胞因子防御对ARDS和其他炎症性疾病患者将是一种有益的治疗方法。